RXI-109 for retinal scarring safe, well tolerated in phase 1/2 study

RXI-109 injection for retinal scarring in neovascular age-related macular degeneration was safe and well tolerated in a phase 1/2 clinical trial, according to a press release from RXi Pharmaceuticals.
The open-label, multi-dose, dose escalation study included three dose cohorts to evaluate safety and tolerability of RXI-109.
Mild to moderate procedure-related adverse events were observed, none of which were drug related, and there were no dose-limiting or serious toxicities, the release said.
In addition, assessment measuring clinical effect found a change in subretinal fibrosis lesion size from

Full Story →